Serum hepatitis B surface antigen levels predict treatment response to nucleos(t)ide analogues

被引：25

作者：

Chen, Chien-Hung ^{[1
,2
]}

Chiu, Yi-Chun ^{[1
,2
]}

Lu, Sheng-Nan ^{[1
,2
]}

Lee, Chuan-Mo ^{[1
,2
]}

Wang, Jing-Houng ^{[1
,2
]}

Hu, Tsung-Hui ^{[1
,2
]}

Hung, Chao-Hung ^{[1
,2
]}

机构：

[1] Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Div Hepatogastroenterol, Kaohsiung 833, Taiwan

[2] Chang Gung Univ, Coll Med, Kaohsiung 833, Taiwan

来源：

WORLD JOURNAL OF GASTROENTEROLOGY | 2014年 / 20卷 / 24期

关键词：

Alanine aminotransferase; Hepatitis B virus; Hepatitis B surface antigen; Nucleos(t)ide analogs; Virological response; SUSTAINED VIROLOGICAL RESPONSE; HBEAG-NEGATIVE PATIENTS; HBV DNA LEVELS; LAMIVUDINE THERAPY; ENTECAVIR THERAPY; VIRUS-INFECTION; HBSAG LOSS; FOLLOW-UP; ACUTE EXACERBATION; ANTIVIRAL THERAPY;

D O I：

10.3748/wjg.v20.i24.7686

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Quantification of hepatitis B surface antigen (HBsAg) has been suggested to be helpful in the management of chronic hepatitis B (CHB) patients. Nucleos(t)ide analogs (NAs) are the therapy of choice for CHB and are used in the majority of CHB patients. NAs are able to induce hepatitis B virus (HBV) viral suppression, normalization of alanine aminotransferase (ALT) levels, and improvement in liver histology. Automated quantitative assays for serum HBsAg have recently become available, facilitating standardized quantification of serum HBsAg. This has led to increased interest in the clinical application of quantitative serum HBsAg for predicting therapeutic response to NAs. Recent studies have shown that a decline in serum HBsAg levels in patients receiving peginterferon may signal successful induction of immune control over HBV, and can therefore be used to predict therapeutic response. NA treatment typically induces a less rapid decline in HBsAg than interferon treatment; it has been estimated that full HBsAg clearance can require decades of NA treatment. However, a rapid HBsAg decline during NA therapy may identify patients who will show clearance of HBsAg. Currently, there is no consensus on the clinical utility of serum HBsAg monitoring for evaluating patient responses to NA therapy. This review focuses on recent findings regarding the potential application of HBsAg quantification in the management of CHB patients receiving NA therapy. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.

引用

页码：7686 / 7695

页数：10

共 68 条

[1]

BLUMBERG BS, 1968, B NEW YORK ACAD MED, V44, P1566

[2] Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D [J].